Eight Months of Serological Follow-Up of Anti-SARS-CoV-2 Antibodies in France: A Study among an Adult Population

被引:0
|
作者
Decarreaux, Dorine [1 ,2 ,3 ]
Sevila, Julie [1 ]
Masse, Shirley [1 ]
Capai, Lisandru [1 ]
Fourie, Toscane [3 ]
Villarroel, Paola Mariela Saba [3 ]
Amroun, Abdennour [3 ]
Nurtop, Elif [3 ]
Vareille, Matthieu [1 ]
Blanchon, Thierry [2 ]
de Lamballerie, Xavier [3 ]
Charrel, Remi [3 ]
Falchi, Alessandra [1 ]
机构
[1] Univ Corse Pascal Paoli, Lab Virol, UR7310 Bioscope, F-20250 Corte, France
[2] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, IPLESP, F-75012 Paris, France
[3] Aix Marseille Univ, Unite Virus Emergents, IHU Mediterranee Infect, INSERM U1207,IRD 190, F-13005 Marseille, France
关键词
COVID-19; seroconversion; long-lasting immunity; antibodies; vaccination; INFECTION; COVID-19;
D O I
10.3390/ijerph192215257
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: Uncertainties remain regarding the nature and durability of the humoral immune response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Aim: This study investigated immunoglobulin G response and neutralizing activity to evaluate the mean antibody concentrations and response duration induced by each vaccination regimen in a French adult population. Methods: A study including blood sampling and questionnaires was carried out from November 2020 to July 2021 with three separate follow-up phases. Spike proteins and neutralizing antibodies were quantified using ELISA and a virus-neutralization test. Results: Overall, 295 participants were included. Seroprevalences were 11.5% (n = 34), 10.5% (n = 31), and 68.1% (n = 201) in phases 1, 2, and 3, respectively. Importantly, 5.8% (n = 17) of participants lost their natural antibodies. Antibody response of participants with only a prior infection was 88.2 BAU/mL, significantly lower than those vaccinated, which was 1909.3 BAU/mL (p = 0.04). Moreover, the antibody response of vaccinated participants with a prior infection was higher (3593.8 BAU/mL) than those vaccinated without prior infection (3402.9 BAU/mL) (p = 0.78). Vaccinated participants with or without prior infection had a higher seroneutralization rate (91.0%) than those unvaccinated with prior infection (65.0%). Conclusion: These results demonstrated that single infection does not confer effective protection against SARS-CoV-2.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population
    Trifonova, Iva
    Ngoc, Kim
    Gladnishka, Teodora
    Ivanova, Vladislava
    Kunchev, Metodi
    Mutafchiyski, Ventsislav
    Christova, Iva
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2023, 37 (01)
  • [2] Detecting Waning Serological Response with Commercial Immunoassays: 18-Month Longitudinal Follow-up of Anti-SARS-CoV-2 Nucleocapsid Antibodies
    Nakagama, Yu
    Komase, Yuko
    Kaku, Natsuko
    Nitahara, Yuko
    Tshibangu-Kabamba, Evariste
    Tominaga, Tomoyo
    Tanaka, Hiroko
    Yokoya, Tomoaki
    Hosokawa, Minako
    Kido, Yasutoshi
    MICROBIOLOGY SPECTRUM, 2022, 10 (04):
  • [3] Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
    Elslande, Jan Van
    Oyaert, Matthijs
    Ailliet, Scott
    Ranst, Marc Van
    Lorent, Natalie
    Weygaerde, Yannick Vande
    Andre, Emmanuel
    Lagrou, Katrien
    Vandendriessche, Stien
    Vermeersch, Pieter
    JOURNAL OF CLINICAL VIROLOGY, 2021, 136
  • [4] Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population
    Caitlin Greenland-Bews
    Rachel L. Byrne
    Sophie I. Owen
    Rachel L. Watkins
    Daisy Bengey
    Kate Buist
    Karina Clerkin
    Camille Escadafal
    Lorna S. Finch
    Susan Gould
    Emanuele Giorgi
    Andy Hodgkinson
    Larysa Mashenko
    Darren Powell
    Helen R. Savage
    Caitlin R. Thompson
    Lance Turtle
    Jahanara Wardale
    Dominic Wooding
    Thomas Edwards
    Ana Cubas Atienzar
    Emily R. Adams
    BMC Infectious Diseases, 23
  • [5] Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population
    Greenland-Bews, Caitlin
    Byrne, Rachel L. L.
    Owen, Sophie I. I.
    Watkins, Rachel L. L.
    Bengey, Daisy
    Buist, Kate
    Clerkin, Karina
    Escadafal, Camille
    Finch, Lorna S. S.
    Gould, Susan
    Giorgi, Emanuele
    Hodgkinson, Andy
    Mashenko, Larysa
    Powell, Darren
    Savage, Helen R. R.
    Thompson, Caitlin R. R.
    Turtle, Lance
    Wardale, Jahanara
    Wooding, Dominic
    Edwards, Thomas
    Atienzar, Ana Cubas
    Adams, Emily R. R.
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [6] Follow-up study of anti-SARS-CoV-2 IgG antibody response in COVID-19 patients up to 6 months after infection
    Eray, Atalay
    Murat, Karamese
    Abdullah, Gumus
    Ihsan, Kahraman
    Royca, Kelesoglu
    Didem, Ozgur
    Ediz, Tutuncu E.
    FUTURE MICROBIOLOGY, 2022, 17 (13) : 1043 - 1049
  • [7] Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study
    Leclercq, Victoria
    van den Houte, Nayema
    Gisle, Lydia
    Roukaerts, Inge
    Barbezange, Cyril
    Desombere, Isabelle
    Duysburgh, Els
    Van der Heyden, Johan
    VIRUSES-BASEL, 2022, 14 (05):
  • [8] About population tests to detect anti-SARS-CoV-2 antibodies
    Kantor, Isabel N.
    Ritacco, Viviana
    MEDICINA-BUENOS AIRES, 2020, 80 : 87 - 88
  • [9] Detection of Anti-SARS-CoV-2 Antibodies
    Jahrsdoerfer, Bernd
    Schrezenmeier, Hubert
    TRANSFUSIONSMEDIZIN, 2021, 11 (03) : 182 - 187
  • [10] Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines
    Gil-Manso, Sergio
    Carbonell, Diego
    Astrid Perez-Fernandez, Veronica
    Lopez-Esteban, Rocio
    Alonso, Roberto
    Munoz, Patricia
    Ochando, Jordi
    Sanchez-Arcilla, Ignacio
    Bellon, Jose M.
    Correa-Rocha, Rafael
    Pion, Marjorie
    BIOMEDICINES, 2022, 10 (07)